Skip to main content
Smart Investors Daily
TE

NASDAQ · TEM

Tempus AI, Inc.

Healthcare · Medical - Healthcare Information Services

$59.61

Down-$4.01 (-6.30%)

Updated Nov 20, 2026, 2:16 AM

SID Score

5.9/10

Composite research score

Smart Money

54/100

Neutral

Market cap
12.67B
P/E ratio
-63.4
Dividend yield
0.00%
52-week range
$40.77 – $89.09
Volume
5.33M
Avg. volume
7M

Price performance · TEM

TEM price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

TEM closed at $59.61 after 21 trading sessions, down 6.58% for the selected period.

Last close
$59.61
Period change
-6.58%
Period low
$59.61
Period high
$84.44
Daily close
View OHLC price history
TEM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$64.63$66.08$59.41$59.615.33M
Nov 18, 2026$63.88$65.28$61.71$63.625.37M
Nov 17, 2026$67.12$67.3135$61.785$63.436.21M
Nov 16, 2026$69.05$69.22$64.55$64.765.07M
Nov 13, 2026$75.65$75.83$68.48$71.605.31M
Nov 12, 2026$75.27$77.70$71.6068$75.894.82M
Nov 11, 2026$82.99$85.10$79.2501$79.434.24M
Nov 10, 2026$82.37$83.4305$78.16$80.544.97M
Nov 9, 2026$77.69$85.75$76.43$84.448.13M
Nov 6, 2026$70.945$76.85$70.22$76.056.29M
Nov 5, 2026$72.35$72.64$65.07$70.4310.01M
Nov 4, 2026$78.735$81.5973$72.75$75.615.94M
Nov 3, 2026$80.75$84.47$77.60$77.806.36M
Nov 2, 2026$74.43$83.4243$70.30$78.4817.03M
Oct 30, 2026$73.26$76.65$70.84$72.2210.46M
Oct 29, 2026$75.14$78.40$75.14$77.844.85M
Oct 28, 2026$72.07$77.52$71.75$76.616.92M
Oct 27, 2026$67.18$72.89$66.50$72.155.09M
Oct 26, 2026$67.61$68.015$64.03$67.163.78M
Oct 23, 2026$63.94$68.145$62.6703$67.6154.69M
Oct 22, 2026$66.10$68.29$61.51$63.816.2M

Latest TEM news

The latest Smart Investors Daily articles mentioning TEM.

TEM research

Overview

Company profile and research snapshot.

Company profile

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$92.14
Implied upside
—
Analysts
19
TEM recent ratings
DateFirmRatingTarget
Nov 19, 2026Freedom Capital MarketsHold—
Nov 19, 2026HC Wainwright & Co.Buy—
Nov 3, 2026HC Wainwright & Co.Buy—
Nov 3, 2026Cantor FitzgeraldOverweight—
Nov 3, 2026JefferiesHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 11, 2026

Tempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual Meeting

CHICAGO, November 11, 2026--Tempus AI, Inc. (NASDAQ: TEM) today announced that six abstracts (including three oral presentations) will be presented at the 2026 Connective Tissue Oncology Society (CTOS) Annual Meeting taking place November 18–21 in Seoul. At this year’s meeting, Tempus will present clinical research on rare mesenchymal tumors, highlighting how advances in molecular diagnosis and classification are unlocking new treatment options.

Yahoo · Nov 10, 2026

Tempus AI (TEM) Surged on Data Business Momentum and MRD Testing Expansion

Baron Capital, an investment management company, released its Q3 2026 investor letter for the “Baron Discovery Fund”. The letter can be downloaded here. In the quarter, the fund declined 4.16% (institutional shares), outperforming the Russell 2000 Growth Index’s -9.39% return, as investors rotated away from the momentum “AI winner” stocks into software and healthcare. The […]

Yahoo · Nov 9, 2026

SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer

SOTERIA Precision Medicine Foundation, a non-profit 501(c)(3) organization, announced a collaboration with Tempus (NASDAQ: TEM) to deliver personalized, data-driven cancer treatment insights and advanced genomic sequencing to members of the U.S. active-duty and veteran military populations. The collaboration supports SOTERIA's Cancer Hunt™ initiative, delivering precision oncology patient navigation with Tempus' comprehensive genomic profiling and AI-enabled diagnostic platform to help identify

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.